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Abstract
Background: Artemisinin-based combination therapy (ACT) is currently the recommended first-line treatment for
uncomplicated malaria infections. However, a significant proportion of ACT is assumed to be of poor quality,
particularly in Africa. In addition, little is known about how treatment-seeking behaviour of individuals or drug price
is associated with drug quality.
Methods: Caregivers of children less than 5 years of age were interviewed on their knowledge of malaria and their
choices for treatment. Artemisinin drugs were then purchased from sellers that caregivers preferred or had
previously patronized. The active ingredients were quantified by nuclear magnetic resonance spectroscopy.
Results: A negative relationship was anticipated between the education level of caregivers and the quality of anti-
malarial drugs purchased. However, of the 33 drugs collected from 16 different shops, only one contained less
than 80% of its purported active ingredient, and most drugs were within 90% of their listed amounts. No link was
found between drug quality and price. Nonetheless, while ACT is the recommended first-line treatment in Ghana,
21% of the drugs collected were artemisinin monotherapy, and 27% of the ACT was not co-formulated. Among
caregivers, higher education was found to be associated with both an increased likelihood of seeking treatment in
a clinic first, as opposed to visiting drug shops or using herbal remedies, and with purchasing drugs from licensed
sellers.
Conclusion: Surprisingly, drug quality was found to be uniformly high and thus no significant relationship
between price, treatment-seeking behaviour and the content of the active ingredients was observed. However,
artemisinin monotherapy, which the WHO considers inappropriate therapy, was still widely available in Ghana in
2010. Monotherapy was more likely to be available in unlicensed vendors where less-educated caregivers generally
shopped. This linkage between education, treatment-seeking behaviour and drug availability suggests that the
global subsidy to reduce the cost of co-formulated ACT can play a significant role in increasing its availability.
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Background
It is estimated that 350 to 500 million Africans fall sick
with malaria each year [1]; many of them have poor
access to public health facilities and rely primarily on
self-medication through the unregulated private and
informal drug sector [2]. A large portion of anti-malarial
medicines sold in Africa are believed to be counterfeit
(fraudulently mislabelled) or substandard (products with
80% or less of the listed active ingredient) [3-5].
Whether drug vendors sell substandard medicines inten-
tionally or unknowingly, low quality drugs increase mor-
bidity and mortality by failing to properly treat malaria
and contribute to the spread of anti-malarial drug resis-
tance [4].
Artemisinin-based combination therapy (ACT) has
been the WHO-recommended option for first-line
malaria treatment since 2001. ACT combines an artemi-
sinin-based active ingredient with another, slower-clear-
ing anti-malarial compound that reduces the likelihood
of resistance emerging to artemisinin [6-8]. ACT can
also act to slow the spread of resistance [9], an impor-
tant issue as resistance to artemisinin has been recently
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substandard ACT both endangers lives and accelerates
the rate at which resistance to artemisinin spreads. Simi-
lar quality problems with the former first-line drugs sul-
phadoxine-pyrimethamine (SP) and chloroquine (CQ)
are believed to have contributed significantly to the
spread of resistance to those drugs [4].
Because artemisinin compounds are derived from the
plant Artemisia annua, which takes a long time to grow
and produces low yields [11], drug production remains
expensive and inefficient [12]. Despite recent increases
in production, arteminisin monotherapy generally cost
ten times more than other drugs [13], and ACT costs
even more than monotherapy. Consequently, sophisti-
cated counterfeits have been reported in Asia [14],
resulting in a number of cases of increased morbidity
and mortality in the early part of the 21
st Century [15].
This generated concern that a similar problem would
emerge in Africa [15,16].
Over the last ten years, numerous studies have mea-
sured drug quality in sub-Saharan Africa [3,17-24].
Although no consistent results have emerged from these
studies, it is still widely believed that counterfeit and
substandard artemisinin drugs are readily available
across Africa [4,25].
Previous studies have not addressed how characteris-
tics of individuals influence the quality of the drugs they
purchase. For instance, evidence suggests that educa-
tional attainment by mothers, who are the main care-
givers, is generally associated with better use of available
health resources [26]. Thus, this study attempted to
examine whether or not there was a relationship
between education, treatment seeking behaviour by
caregivers and the quality of the artemisinin drugs avail-
able at the places where they typically buy drugs follow-
ing guidelines for field surveys of the quality of
medicines [27]. Drug quality was assessed quantitatively
using nuclear magnetic resonance (NMR) spectroscopy.
Methods
Study participants
Drug purchasing habits and the quality of ACT were
studied in two peri-urban neighbourhoods (Osu and
Osu Klottey) in Accra, Ghana. From July to August
2009 interviews were conducted with individuals living
in Kokrobitey, a fishing village on the southern coast of
Ghana about 19 miles west of Accra. All interviews
were conducted in English about disease awareness and
treatment-seeking behaviour (see guided questions in
Additional file 1). Eligible participants were parents 15-
50 years old with at least one child under five years of
a g ea n dr e s i d i n gi nK o k r o b i t e yv i l l a g ea tt h et i m eo f
study. Eligible participants were invited to participate
during routine home visits. All caregivers that met
requirements during visits on randomly selected days
were invited to participate. There were no refusals.
Informed and signed consent was obtained from each
study participant according to the Institutional Review
Board of Princeton University’s confidentiality and con-
sent guidelines (Protocol No. 4450).
Drug sampling
Drugs were collected by a single non-native individual in
J a n u a r y2 0 1 0f r o ma l lo ft h ev e n d o r sm e n t i o n e db yt h e
study participants. Vendors were located in the Osu,
Makola and Kaneshie Markets near the city of Accra.
Establishments were categorized as licensed sellers if
they had at least one licensed pharmacist or medical
professional. Samples of artemisinin combination drugs
were requested, but any artemisinin-related drug avail-
able was purchased. Samples of both combinations and
monotherapy were acquired in a variety of formulations
including tablets, powders, and syrups. Drug packaging
was examined carefully for signs of tampering or
counterfeiting.
Preparation of drug samples
Three samples of each drug were homogenized and dis-
solved in either chloroform (artemether, dihydroartemisi-
nin) or methanol (artesunate) over a 2-3 h period. The
volume of solvent used for the extraction was adjusted to
maintain a constant ratio between the solvent and the tar-
get drug (2 mg/ml for artemether drugs, 5 mg/ml for arte-
sunate drugs, and 5 mg/ml for dihydroartemisinin).
Samples were centrifuged for 10 min at 10,000 × g. An ali-
quot (1 ml) of each supernatant was transferred to a fresh
tube and dried under a stream of N2 gas. Samples were re-
dissolved in 1 ml of the corresponding perdeuterated sol-
vent and 600 μL were transferred to 5 mm NMR tubes for
quantitative analysis. Samples that showed lower than
expected levels of drug were re-dissolved at twice the ori-
ginal dilution (2.5 mg/ml) and re-analysed by NMR. This
step was included to ensure that solubility limits were not
influencing our observed concentrations.
NMR data analysis
NMR is a well-established tool for identifying and quan-
tifying small molecules in complex mixture [28], and
previous studies have used NMR to identify counterfeit
drugs from field samples [29,30]. One dimensional
1H
NMR spectra were collected on a Bruker Advance 500
MHz spectrometer equipped with a triple resonance
cryoprobe. Spectra were acquired in four transients with
four steady-state transients, an acquisition time of 4 s
and initial delay of 11 s. The long recycle delay
employed in this study minimizes quantitative artifacts
related to differential T1 relaxation between resonances.
Data were Fourier transformed, zero filled, phased, and
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data analyses were performed using the open-source
rNMR software package [31]. Drug resonances were
identified and quantified using established methods [28].
Briefly, standards of each drug were prepared at multi-
ple concentrations (e.g. 2, 5, 10, and 50 mM; N = 3 per
concentration) and two or more non-overlapped reso-
nances were identified for each compound (Additional
file 2). The slope of the concentration versus intensity
curve was then determined for each resonance by linear
regression (Additional file 3). This regression statistic
was then used to calculate concentrations of drugs
observed in the test samples. For artemether-lumefan-
trine samples, standards were prepared from the refer-
ence drug samples for artemether (Sigma) and
lumefantrine (Sigma) as well as from a Coartem
® refer-
ence standard provided by Novartis. Reported results
a r ef o rt h eC o a r t e m
® reference standard. All other
drugs are reported relative to purchased drug standards
(Sigma). All NMR data were collected at the NMR facil-
ity at Princeton University.
IC50 studies
To cross validate the analytical results with a biological
assay, drug concentrations observed in the NMR assay
were compared to IC50 values derived from the same
samples. Plasmodium falciparum cultures (3D7) were
maintained using established methods [29]. Briefly, para-
sites were cultured in washed human erythrocytes incu-
bated in RPMI 1640 medium (Sigma) supplemented
with Albumax (Invitrogen, 2.5 g/L), HEPES (25 mM),
hypoxanthine (100 μM), NaHCO3 (24 mM), and genta-
mycin (50 ng/L). Cultures were synchronized using sor-
bitol (5% sorbitol in PBS for 5 min at 37°C) and grown
until they reached 2% parasitaemia. Drugs were serially
diluted into 96-well plates (440 nM to 13 pM) and ring-
stage parasites were aliquoted into each well (0.5% para-
sitaemia and 2% HCT, final). Plates were incubated for
72 h at 37°C, then frozen for 48 h at -20°C. Plates were
then thawed for 3 h at room temperature and a 100 μl
of culture was transferred to optical plates containing
100 μl of SYBR green I (Sigma) in lysis buffer (20 mM
Tris-HCl; 5 mM EDTA; 0.08% TritonX-100; 0.008%
saponin in PBS). Fluorescence was measured using a
BioTek plate reader with excitation and emission wave-
lengths of 485 nm and 535 nm, respectively. IC50 values
for each drug were calculated using ICEstimator [32].
Role of the funding source
The institutions that supported this work had no role in
study conception, data collection, analysis and interpre-
tation, writing of the manuscript, or decision to submit
for publication. All authors had full access to all data in
the study.
Results
Field interviews
From July to August 2009, interviews were conducted in
34 households near Accra, Ghana. Both parents were
interviewed in two households, while only the mother
was interviewed in 32 households. Study participants
were 20-43 years old, and all but two were married. All
parents were the primary caregivers for at least one
child under five. Table 1 lists the background profile
information such as the age, education, household size
and occupation of the parents who participated in the
study (see Additional file 4 for full data on all
caregivers).
All parents recognized malaria as a widespread disease
transmitted through mosquitoes, and engaged in some
form of preventive behaviour, such as burning mosquito
coils and draining areas of still water near the house. All
study participants had previously treated themselves
and/or their children for malaria. All parents reported
previously having malaria, and 25 (69%) parents
reported having dealt with malaria in their children.
Thirty three (92%) parents reported fever, shivering and
chills, and headache as the predominant symptoms of
malaria they looked for in their children.
Table 1 Profile of study participants
Characteristics N (%)
Age
15-24 8 (22%)
25-34 24 (67%)
35-44 4 (11%)
Educational Status
No formal education 2 (6%)
Primary (1-6) 28 (78%)
Secondary (7-12) 6 (17%)
Total living children living in household
1 5 (14%)
2 11 (31%)
3 8 (22%)
4 7 (19%)
5 3 (8%)
6 2 (6%)
Living children under five in household
1 15 (42%)
2 15 (42%)
3 6 (17%)
Occupation
farmer 11 (31%)
market vendor 21 (58%)
housewife 2 (6%)
student 1 (3%)
unemployed 1 (3%)
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for treatment were market drug vendors, herbal reme-
dies, and public health facilities, respectively (Table 2).
While all but one caregiver (97%) listed the drug shop/
medicine seller as one of their top three choices for
seeking treatment, nearly as many (86%) listed tradi-
tional/herbal remedies. Level of education influenced
the preferred source of treatment and perceived quality
at medicine sellers that parents most frequently visited.
Five of the six parents with a secondary education or
higher listed a public or private health facility as their
first choice for seeking malaria treatment, and five of six
also mentioned licensed shops when asked to give
examples of their preferred medicine sellers (the last
one did not list a preference). In addition, these parents
were more likely not to list traditional/herbal remedies
at all.
Drug quality
In total, 33 artemisinin-based malarial medicines were
purchased from licensed urban pharmacies and informal
market vendors cited as anti-malarial drug sources by at
least one parent (Additional file 5). Nine of the samples
were purchased from five licensed sellers in Osu and 24
from 11 informal sellers in Makola and Kaneshie Mar-
kets. Fifteen of the drugs were artemether-based drugs,
12 of the drugs were artesunate drugs and the remain-
ing six were dihydroartemisinin drugs. At two of the
informal sellers, ACT was not available, so artemisinin
monotherapies were purchased instead. In addition,
artemisinin monotherapies were readily available and
purchased at four other vendors including one licensed
seller.
The drugs collected were produced by 13 different
manufacturers. The most common was Bliss GVS, an
Indian company, which accounted for almost half of all
the drugs purchased, followed by companies from China
and Ghana. All the drugs were purchased in January
2010, and all but two had a remaining shelf life of at
least six months. Of the ones with a shelf life less than
six months, both were purchased separately from two
unlicensed drug vendors in Makola Market and had
listed expiration dates of Nov 2009 and May 2010.
Despite the expiration date, all drugs were included in
the final analysis.
All the artemether-based drugs collected were avail-
able in combination with lumafantrine; 10 were co-for-
mulated combination tablets, three were dry powder
formulations, and two had separate tablets for arte-
mether and lumefantrine. Eight of the 12 artesunate-
based drugs were available as an ACT, however only
three of them were co-formulated. Of the six dihydroar-
temisinin samples, three were monotherapy, two were
co-formulated with piperaquine (one of which was a
powder) and the final sample was a tri-formulated tablet
with piperaquine and trimethoprim.
Drugs were quantified using established NMR meth-
ods [28,31]. Only one of the artemether-based drugs, a
powder formulation, was found to be below 80% of the
expected amount (Figure 1 and Additional file 6 and
Additional file 7). However, powders can be problematic
because they can absorb water and thereby artificially
deflate yields. In addition, the relatively large amount of
excipients present in powder formulations can affect
drug solubility and can create other solution chemistry
problems that interfere with quantitative analysis. Thus,
the low yield observed in this sample is inconclusive
and may be due to absorption of water or solution
chemistry problems rather than a reflection that this
drug is of substandard quality.
For artesunate-based formulations, observed drug
levels consistently matched the content stated on the
package (Figure 2 and Additional file 8 and Additional
file 9). Two non-tablet drugs, #16 (co-formulated suppo-
sitory) and #17 (amodiaquine suspension only) were
excluded because the extraction method was not opti-
mized for these drugs. Number 18 was opened prior to
testing so was also excluded from the analysis. For dihy-
droartemisinin-based formulations, two drugs were
below their expected levels (Figure 3); one sample (#28)
was a tri-formulated drug and the other was a powder
mixture (#33). Observed levels of both drugs were con-
sistent across multiple dilutions (Additional file 10),
indicating that solubility limits were not influencing
yields. As mentioned previously, powder formulations
are subject to quantitative problems, making it difficult
to determine whether the drug was of substandard qual-
ity. However, based on these results it can be concluded
that the level of dihydroartemisinin in the tri-formulated
drug was less than the amount stated on the package.
To assess the efficacy of NMR as a quantitative tool, the
observed concentrations prior to dilution of the dihy-
droartemsinin drugs were cross-validated with a biologi-
cal activity assay. IC50 values of the sample drugs
relative to both a dihydroartemisin standard and a co-
formulated drug standard, Eurartesim™, were measured.
The resulting IC50 values showed significant correlation
Table 2 Reported priority of malaria treatment sources
Source of treatment First
choice
Second
choice
Third
choice
Drug shop or market medicine
vendor
17 (47%) 11 (31%) 7 (19%)
Traditional and herbal remedies 9 (25%) 16 (44%) 6 (17%)
Public health facility 6 (17%) 6 (17%) 17 (47%)
Private clinic 2 (6%) 3 (8%) 6 (17%)
Other (leftover/borrowed
medicines)
2 (6%) 0 (0%) 0 (0%)
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activity (Additional file 11).
Discussion
The widespread use of the highly effective anti-malarial
d r u g ,C Q ,l e dt ot h ee m e r g e n c eo fr e s i s t a n c ea n dt h e
eventual demise of the first malaria eradication effort.
During the 1980s, circulation of substandard CQ anti-
malarial medicines in Africa contributed to the subse-
quent spread of CQ resistance in parts of eastern Africa
[4,20]. Sulphadoxine-pyrimethamine, the first-line drug
widely adopted after CQ resistance emerged, suffered a
similar fate in the 1990s [4]. The recent introduction of
widespread artemisinin use has revived talk of malaria
eradication [33]. However, sub-therapeutic use of this
drug due to counterfeiting may imperil its efficacy and
spread resistance faster. This is particularly true of drug
purchases from unlicensed sellers and the informal drug
market, which is the primary source of pharmaceutical
products for patients or caregivers seeking home-based
malaria treatment in many rural areas where the formal
health system does not reach [34]. In this study, the link
between consumer education, treatment-seeking beha-
viour and the quality of the drugs purchased was
examined.
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Figure 1 Artemether-lumefantrine. Percentage of each drug
found relative to the stated quantity on the box as measured
against Coartem
® standard (Novartis). * powder formulations for
which the extraction method was not optimized.
E
s
t
i
m
a
t
e
d
 
D
r
u
g
 
A
m
o
u
n
t
 
(
%
)
0
20
40
60
80
100
E
s
t
i
m
a
t
e
d
 
D
r
u
g
 
A
m
o
u
n
t
 
(
%
)
0
20
40
60
80
100
1
7
.
 
C
a
m
o
q
u
i
n
 
P
l
u
s
‡
1
9
.
 
L
e
v
e
r
 
A
r
t
e
s
u
n
a
t
e
†
2
0
.
 
G
s
u
n
a
t
e
†
2
1
.
 
L
e
v
e
r
 
A
r
t
e
s
u
n
a
t
e
†
2
2
.
 
A
r
s
u
a
m
o
o
n
2
3
.
 
C
o
−
A
r
t
e
s
u
n
2
4
.
 
G
s
u
n
a
t
e
 
1
0
0
 
K
i
t
2
5
.
 
G
s
u
n
a
t
e
 
1
0
0
 
K
i
t
2
6
.
 
C
o
a
r
s
u
c
a
m
2
7
.
 
M
a
l
a
s
a
t
e
 
2
0
0
†
A) Artesunate
B) Amodiaquine
Figure 2 Artesunate-amodiaquine.P e r c e n t a g eo fe a c hd r u g
found relative to the stated quantity on the box as measured
against a reference standard (Sigma). † artesunate monotherapy
drugs; ‡ amodiaquine was a liquid suspension that was not
optimized for extraction method. Number 16 was a suppository for
which extraction was not optimized and number 18 was opened
prior to analysis.
Klein et al. Malaria Journal 2012, 11:110
http://www.malariajournal.com/content/11/1/110
Page 5 of 8The results from field interviews suggest that
increased education was associated with an increased
likelihood to patronize licensed drug sellers and to rely
less heavily on traditional remedies. This is in accord
with research showing increased education of mothers is
associated with a higher use of western health services
[26]. Increased education is also often associated with
increased wealth; thus it was not surprising that there
was a moderate cost difference between shops that had
licensed sellers and those that did not. At licensed
shops, the average cost of drugs was 6.63 cedis (US$
4.65) compared to 5.07 cedis (US$ 3.55) at non-licensed
shops. This effect was apparent even if the monotherapy
drugs, which were more likely to be sold at non-licensed
shops and which were on average just over half the cost
of the ACT (6.05 cedis vs 3.44 cedis or US$ 4.24 vs US$
2.41), were excluded.
Based on prior reports [3,14,17-19,24], the expectation
was that a large percentage of the drugs would be of
low quality. However, consistently high drug quality
across the samples collected for this study was observed.
Only three drugs fell below 80% of the expected level,
the pass/fail threshold used by other studies [3,18]. Two
of these drugs were powder formulations, which are
subject to a variety of analytical problems that prevent
us from drawing any definitive conclusions about their
quality. However, the third drug was a tablet formula-
tion that showed 60% of the expected drug quantity
across multiple dilutions. From these data, it can be
concluded that the amount of dihydroartemisinin con-
tained in sample 28 was less than the amount stated on
the package.
Despite high overall drug quality, the number of arte-
misinin monotherapy drugs available for purchase sug-
gests a deeper structural problem in the drug market.
While ACT is the recommended first-line treatment in
Ghana, and the WHO has called for an end to the pro-
duction and marketing of artemisinin monotherapy,
seven (21%) of the drugs purchased were artemisinin
monotherapy, one of which was purchased at a licensed
seller. Co-formulation was also a problem; seven forms
(27%) of ACT were not co-formulated. Where drugs are
not co-formulated, patients are likely to inadvertently or
even knowingly use the drugs as monotherapy [6].
Despite vast cost differences, no linkage was found
between the price and the quality of the drug. This
result may be due to the limited number of samples col-
lected or the fact that the drugs were purchased by a
non-native person. However, this result is consistent
with a large multi-country study, which found that price
offered only a weak signal of drug quality [35]. Also, no
real difference between the quality of drugs sold at
licensed sellers versus unlicensed sellers was found,
though only the quality of artemisinin-based drugs were
sampled, and these are significantly more expensive
than other drugs, and have been the focus of control
efforts in Ghana [18].
In addition to the small sample size and the fact that
the drugs were collected by a non-Ghanaian, no dissolu-
tion analysis was performed, samples were not blinded
before analysis, and while packaging was examined care-
fully, no genuine examples were available to compare
against. Another limitation of this study is that the bioa-
vailability and efficacy of drugs can be influenced by
excipients [36], which were not tested in this study. This
limitation was partially addressed by comparing NMR-
observed levels of the active ingredients to biological
activity in an IC-50 assay. These data show that all of
the formulations tested were effective in vitro despite
their diverse excipients.
While no link was found between price and quality, it
should be noted that the absolute price levels in 2010
were extremely high, averaging about 5.5 Ghanaian
cedis (US$ 3.85), with a minimum of 2.8 cedis (US$
1.96) and a maximum of 12 cedis (US$ 8.41). These
rates are well above the cost that most ordinary Gha-
naians can afford - the gross-national income per capita
is estimated to be US$ 1,327 (Ghana Statistical Services).
This suggests that the Affordable Medicines Facility -
malaria (AMFm) may be able to play a critical role in
places such as Ghana. Designed as a global subsidy to
reduce the cost of artemisinin co-formulated products,
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apy and substandard drugs, as well as expand access to
ACT [6,37]. All of the drugs in this study were collected
prior to the implementation of the subsidy. Thus, this
report can serve as a benchmark in examining the
impact of the AMFm subsidy both for quality of ACT
and the availability of monotherapy, which is a signifi-
cant problem for containing the spread of artemisinin
resistance that has recently emerged in Cambodia [10].
Conclusions
The results from this study suggest that the quality of
drugs available for purchase in some parts of Ghana in
2010 was surprisingly high. These findings also indicate
that recent high-profile reports [3,4,18] claiming low
overall drug quality in Africa should not be generalized;
some communities, such as the peri-urban neighbour-
hoods, Osu and Osu Klottey, in Accra, Ghana are
receiving quality products. One distinction between this
study and those reporting significant quality problems is
the use of NMR. Although NMR is not applicable to
field studies, it is a highly quantitative tool [38,39] that
is routinely used for drug quality analyses [40,41].
Future field studies should cross-validate colorimetric
assays [3,17,18] with established quantitative tools such
as NMR or high-performance liquid chromatography
mass spectrometry.
While the sample size of this study was small, the
sampling method purposely sought places that may pro-
vide lower quality drugs, yet there was no apparent link
between treatment-seeking behaviour and the quality of
drugs purchased. Individuals with more education are
more likely to seek treatment at a clinic and purchase
drugs from licensed vendors, but the content of the
active ingredients do not seem to vary significantly.
However, the high cost of the d r u g sp r e s e n t sas i g n i f i -
cant access barrier. In addition, from the point of view
of the long-term efficacy of the artemisinin, the contin-
ued availability of artemisinin monotherapy remains a
significant problem. As the scale of artemisinin produc-
tion continues to increase, it is important that countries
remain vigilant about the possible problems of counter-
feiting, but it is also important that the use of co-formu-
lated artemisinin combination therapy is expanded to
save lives and reduce the rate at which resistance to
artemisinin spreads.
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